SEC Comment Letter for Scinai Immunotherapeutics Ltd. (SCNI) (CIK 0001611747) (SCNI) — May 30, 2019
Scinai Immunotherapeutics Ltd. (SCNI) (CIK 0001611747)
Date: May 30, 2019 · CIK: 0001611747 · Accession: 0000000000-19-009179
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-230484
Letter
May 30, 2019 Ron Babecoff Chief Executive Officer and Director BiondVax Pharmaceuticals Ltd. Jerusalem BioPark, 2nd floor Hadassah Ein Kerem Campus Jerusalem, Israel Re:BiondVax Pharmaceuticals Ltd. Amendment No. 2 to Registration Statement on Form F-1 Filed May 30, 2019 File No. 333-230484 Dear Dr. Babecoff: We have reviewed your amended registration statement and have the following comment. Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to your registration statement and the information you provide in response to this comment, we may have additional comments. Amendment No.2 to Form F-1 Filed May 30, 2019 Exhibits 1.Please file the instrument that defines the rights of the subscription rights being registered, an opinion of counsel as to the legality of the securities being registered and consent as exhibits. See Item 601(b)(4), Item 601(b)(5), and Item 601(b)(23) of Regulation S-K.
FirstName LastNameRon Babecoff Comapany NameBiondVax Pharmaceuticals Ltd. May 30, 2019 Page 2 FirstName LastName Ron Babecoff BiondVax Pharmaceuticals Ltd. May 30, 2019 Page 2 You may contact Jeffrey Gabor at 202-551-2544 or Suzanne Hayes at 202-551-3675 with any questions. Sincerely, Division of Corporation Finance Office of Healthcare & Insurance cc: Mark Hamilton, Adv.
Show Raw Text
May 30, 2019
Ron Babecoff
Chief Executive Officer and Director
BiondVax Pharmaceuticals Ltd.
Jerusalem BioPark, 2nd floor
Hadassah Ein Kerem Campus
Jerusalem, Israel
Re:BiondVax Pharmaceuticals Ltd.
Amendment No. 2 to Registration Statement on Form F-1
Filed May 30, 2019
File No. 333-230484
Dear Dr. Babecoff:
We have reviewed your amended registration statement and have the following
comment.
Please respond to this letter by amending your registration statement and providing the
requested information. If you do not believe our comment applies to your facts and
circumstances or do not believe an amendment is appropriate, please tell us why in your
response.
After reviewing any amendment to your registration statement and the information you
provide in response to this comment, we may have additional comments.
Amendment No.2 to Form F-1 Filed May 30, 2019
Exhibits
1.Please file the instrument that defines the rights of the subscription rights being registered,
an opinion of counsel as to the legality of the securities being registered and consent as
exhibits. See Item 601(b)(4), Item 601(b)(5), and Item 601(b)(23) of Regulation S-K.
FirstName LastNameRon Babecoff
Comapany NameBiondVax Pharmaceuticals Ltd.
May 30, 2019 Page 2
FirstName LastName
Ron Babecoff
BiondVax Pharmaceuticals Ltd.
May 30, 2019
Page 2
You may contact Jeffrey Gabor at 202-551-2544 or Suzanne Hayes at 202-551-3675 with
any questions.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Mark Hamilton, Adv.